Cargando…

Correction: Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature

Detalles Bibliográficos
Autores principales:	Chan, David L., Pavlakis, Nick, Shapiro, Jeremy, Price, Timothy J., Karapetis, Christos S., Tebbutt, Niall C., Segelov, Eva
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4583271/ https://www.ncbi.nlm.nih.gov/pubmed/26406241 http://dx.doi.org/10.1371/journal.pone.0138916

Ejemplares similares

Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature
por: Chan, David L., et al.
Publicado: (2015)

The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials
por: Segelov, E, et al.
Publicado: (2014)

The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours
por: Foo, Tiffany, et al.
Publicado: (2022)

ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours
por: Segelov, Eva, et al.
Publicado: (2016)

MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG)
por: Siu, Ho Wai Derrick, et al.
Publicado: (2021)

The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT]
por: Clarke, Stephen John, et al.
Publicado: (2020)

European-Australasian consensus on the management of advanced gastric and gastro-oesophageal junction cancer: current practice and new directions
por: Pavlakis, Nick, et al.
Publicado: (2022)

Pathological responses after angiogenesis or EGFR inhibitors in metastatic colorectal cancer depend on the chemotherapy backbone
por: Carrasco, J, et al.
Publicado: (2015)

Brain metastasis in advanced colorectal cancer: results from the South Australian metastatic colorectal cancer (SAmCRC) registry
por: Tapia Rico, Gonzalo, et al.
Publicado: (2017)

The effect of anti-angiogenic agents on overall survival in metastatic oesophago-gastric cancer: A systematic review and meta-analysis
por: Chan, David L., et al.
Publicado: (2017)

Patients’ Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer
por: Blinman, Prunella, et al.
Publicado: (2020)

Prognostic significance of mucinous histology in left‑sided metastatic colorectal cancers with wild‑type RAS and evaluation of backbone chemotherapy regimens
por: Arikan, Rukiye, et al.
Publicado: (2023)

Refractory Metastatic Colorectal Cancer: Current Challenges and Future Prospects
por: Lam, Marissa, et al.
Publicado: (2020)

Circulating epigenetic biomarkers for detection of recurrent colorectal cancer
por: Symonds, Erin L., et al.
Publicado: (2020)

Identifying and Prioritizing Gaps in Neuroendocrine Tumor Research: A Modified Delphi Process With Patients and Health Care Providers to Set the Research Action Plan for the Newly Formed Commonwealth Neuroendocrine Tumor Collaboration
por: Segelov, Eva, et al.
Publicado: (2016)

Chemotherapy and Targeted Agents in the Treatment of Elderly Patients with Metastatic Colorectal Cancer
por: Tuca, Albert, et al.
Publicado: (2020)

Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone
por: ten Hoorn, Sanne, et al.
Publicado: (2021)

An Australian translational Study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT]
por: Clarke, Stephen, et al.
Publicado: (2013)

Systematic Review and Meta-Analysis on the Role of Chemotherapy in Advanced and Metastatic Neuroendocrine Tumor (NET)
por: Wong, Matthew H., et al.
Publicado: (2016)

Association of BMI with overall survival in patients with mCRC who received chemotherapy versus EGFR and VEGF-targeted therapies
por: Patel, Gargi S, et al.
Publicado: (2015)

Personalized treatment for advanced colorectal cancer: KRAS and beyond
por: Patel, Gargi Surendra, et al.
Publicado: (2013)

Backbone.js essentials
por: Walker, Jeremy
Publicado: (2015)

Evaluating the Time Toxicity of Cancer Treatment in the CCTG CO.17 Trial
por: Gupta, Arjun, et al.
Publicado: (2023)

New drug developments in metastatic gastric cancer
por: Tan, Aaron C., et al.
Publicado: (2018)

Institutional modelling: Adding social backbone to agent-based models
por: Ghorbani, Amineh
Publicado: (2022)

Can we accurately report PTEN status in advanced colorectal cancer?
por: Hocking, Christopher, et al.
Publicado: (2014)

Treatment of 5-fluorouracil refractory metastatic colorectal cancer: an Australian population-based analysis
por: Damianovich, D, et al.
Publicado: (2007)

backbone: An R package to extract network backbones
por: Neal, Zachary P.
Publicado: (2022)

Evaluation of (18)F-FMISO PET and (18)F-FDG PET Scans in Assessing the Therapeutic Response of Patients With Metastatic Colorectal Cancer Treated With Anti-Angiogenic Therapy
por: Lee, Sze Ting, et al.
Publicado: (2021)

Backbone: An R package for extracting the backbone of bipartite projections
por: Domagalski, Rachel, et al.
Publicado: (2021)

Do metastatic colorectal cancer patients who present with late relapse after curative surgery have a better survival?
por: Broadbridge, V T, et al.
Publicado: (2013)

Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
por: Chong, G, et al.
Publicado: (2005)

The Backbones of the Poor
Publicado: (1888)

Bones and Backbones
Publicado: (1888)

Hepatic arterial chemotherapy for metastatic colorectal carcinoma.
por: de Takats, P. G., et al.
Publicado: (1994)

Enduring complete metabolic response in metastatic adenocarcinoma of the gastro-oesophageal junction
por: Li, Minmin, et al.
Publicado: (2014)

Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer
por: Jonker, D J, et al.
Publicado: (2014)

Reply: Comment on ‘Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer'
por: Rowland, Andrew, et al.
Publicado: (2015)

Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy
por: Tsavaris, Nicolas, et al.
Publicado: (2002)

Prolonged survival in metastatic colorectal cancer following chemotherapy
por: Paul, Doru, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_qcqqpf08v041lh59kteg32dqoq